6 results
Objectives: The following trial objectives for adult patients with plasma therapy-resistantAtypical Hemolytic-Uremic Syndrome (aHUS) are to:Primary:• Assess the effect of eculizumab to reduce thrombotic microangiopathy (TMA) asindicated by…
Objectives: The following trial objectives for adolescent patients (from 12 and up to 18 years of age) with plasma therapy-sensitive Atypical Hemolytic-Uremic Syndrome (aHUS) are to:Primary:* Assess the effect of eculizumab on TMA-Event Free status…
Objectives: The following trial objectives for adult patients with plasma therapy-resistantAtypical Hemolytic-Uremic Syndrome (aHUS) are to:Primary:• Assess the effect of eculizumab to reduce thrombotic microangiopathy (TMA) asindicated by…
To evaluate the safety and efficacy of 177Lu-PSMA RLT in patients with R/M ACC and SDC with PSMA ligand uptake.
The primary objective of this study is to determine the accuracy of the delta PCO2 (PaCO2-tcPCO2) and delta PO2 (tcPO2 -cPO2) levels for the detection of sepsis. The secondary aims are to determine the factors that influence delta PCO2 and delta PO2…
The primary objective of this study is to determine the relation of delta PO2 (PaO2-tcPO2) and delta PCO2 (tcPCO2-cPCO2) levels to sepsis. The secondary aims are to determine the factors that influence delta PO2 and delta PCO2 and to determine the…